Loading...
•
Sep 30, 2020
Regulus Therapeutics Q3 2020 Earnings Report
Regulus Therapeutics reported financial results for the third quarter ended September 30, 2020, and provided a corporate update.
Key Takeaways
Regulus Therapeutics reported revenue of $5.0 million for the third quarter of 2020, primarily from the completion of material transfers to Sanofi. The company achieved milestones from its collaboration with Sanofi, reducing outstanding debt to $4.7 million and extending the interest-only period through the end of 2021. The first patient was dosed in the Phase 1b clinical trial of RGLS4326 for ADPKD.
Dosed first patient in Phase 1b clinical trial of RGLS4326 for ADPKD.
Achieved $10 million in milestones from Sanofi collaboration.
Reduced outstanding debt to $4.7 million.
Extended interest-only period through the end of 2021.
Regulus Therapeutics
Regulus Therapeutics
Forward Guidance
Regulus anticipates availability of results from the first cohort of the Phase 1b clinical trial of RGLS4326 by the end of Q1 2021 and plans to commence IND-enabling activities for its HBV program.